Senolytic drugs

A year in Longevity: progress perspectives

2020's journey to extending healthy human Longevity. The journey to Longevity has many stages, whether it's a clinical pipeline, gaining regulatory approval for a drug,...

A year in Longevity: founders’ perspectives

Speaking to the innovators behind some of Longevity’s most exciting companies. Continuing our look back at some of the highlights of 2020, we thought we’d...

Eliminating senescent cells to improve heart attack recovery

A drug that exterminates senescent cells improves recovery after a heart attack, according to new research, and could pave the way for a new...

NAD boosting to reverse senescence and inflammaging

Senescent cells promote NAD tissue decline during aging through CD38 enzymes which can now become a novel therapeutic target. Nicotinamide adenine dinucleotide (NAD) is a...

Silicon Valley is waking up to Longevity and senolytics

Silicon Valley's Rubedo Life Sciences closes $12m seed round for proprietary drug discovery platform that targets senolytics. Following-on from BioAge's funding announcement, another biotech start-up...

Senescence: a new weapon in the fight against cancer

Targeting senescent “zombie” cells may improve cancer survival rates. How well women with cervical cancer respond to treatment (and survive) correlates with the level of...

Let’s initiate trials of potential geroprotective therapies

Dr Lynne Cox explains the importance of geroprotectors – especially during COVID-19. This month The Lancet launches its own journal on Longevity, publishing clinically-focused Longevity and...

AgelessRx and funding an IRB-approved rapamycin trial

Rapamycin could be the PEARL in the Longevity oyster as new human trial seeks funding. AgelessRx is a platform that sells drugs and supplements including...

OneSkin launches topical senetherapeutic skin treatment

Extending skinspan with non-invasive senetherapeutic proprietary peptide. OneSkin is a Longevity company on a mission to transform the way we think about skin. Today the...

Big pharma enters senolytic drug discovery programme

Japanese pharma Taisho teams with Insilico to discover novel molecules that will tackle aging. It was announced today that Taisho Pharmaceutical and Insilico Medicine have...

Senolytics applied to the rejuvenation of organs

Scientists from Brigham & Women’s Hospital show that senolytics can rejuvenate organs from elderly donors by eliminating senescent cells and alleviating age-associated inflammation. In a...

Senolytics research shows Longevity progress

Senolytic research in humans may be in its infancy, but there is reason for cautious optimism. Last week we reported on biotech company UNITY's decision...

Elysium publishes positive results from two studies for Basis

Encouraging news from Elysium Health illustrates that the Longevity supplements market is building clinical and commercial traction. In December 2019, Elysium announced a $40m Series...

Taking NAD+ to the next level

Nuchido’s systems pharmacology approach yields NAD+ supplement that claims to boost levels by 242%!    A new player in the NAD+ supplement market has arrived...

UNITY cuts lead program after clinical trial fail

Company to focus on ophthalmologic and neurologic programs as Phase 2 knee osteoarthritis clinical study fails to meet primary endpoint. Senolytic therapy developer UNITY...

Juvenescence (2): “It’s all about prevention, and that’s incredibly disruptive”

Juvenescence's Greg Bailey on democratising healthcare, paradigm shifts and disruptive technologies. Yesterday we published the first part of our interview with Greg Bailey, CEO of...

Juvenescence (1): from strength to strength in R&D and investment firepower

Juvenescence's Greg Bailey on transformative scientific opportunities, immuno-resilience, modifying aging and funding. Continuing our series of interviews with our Advisory Panel members, we spoke to Greg...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...

SENISCA seeks funding for senescence reversal

University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology. Deep in the labs at the...

Longevity investment: Apollo aims for the moon

Co-founder of Longevity-focused investment firm shows you can target aging AND appeal to biotech investors. Founded in 2016, Berlin and Boston-based Apollo already boasts an...
ChromaDex TruNiagen
whoop

Latest articles